Check out our free and informative ezines and sign up now
German MorphoSys has submitted a clinical trial application (CTA) to begin a Phase I trial using the HuCAL-derived antibody MOR103 for the treatment of rheumatoid arthritis.
MorphoSys said it plans to reveal the target molecule of its lead antibody program MOR103 and information on the trial design in January.
The company has 40 therapeutic antibody programs and partnerships with several firms, including Bayer-Schering, Novartis and Roche.
ePublishing :: CMS, Hosting & Web Development | © Copyright